




**Convocatorias 2019-2020 del SC1.  
Innovative Medicines Initiative  
European Innovation Council**

**Reunión CCAA  
23.05.2018**



**Juan E. Riese PhD MBA**

Punto Nacional de Contacto – Reto Social 1 H2020 & IMI2  
Experto Nacional en el Comité de Programa Reto Social 1  
Oficina de Proyectos Europeos  
*Subdirección General de Programas Internacionales  
de Investigación y Relaciones Institucionales*



- 
1. Actualización al Reto Social 1 de HORIZON 2020
  2. Actualización a IMI2
  3. Actualización opciones European Innovation Council

- 
1. Actualización al Reto Social 1 de HORIZON 2020
  2. Actualización a IMI2
  3. Actualización opciones European Innovation Council

# Hacia las convocatorias de SC1 2018-2019-2020

## 7 prioridades repartidas en 3 áreas

### Area 1. Better health and care, economic growth and sustainable health systems **(Topics BHC)**

1. Personalised medicine
2. Innovative health and care industry
3. Infectious diseases and improving global health
4. Innovative health and care systems – Integration of care
5. Decoding the role of the environment for health and well-being

### Area 2. Digital transformation in health and care **(Topics DTH)**

### Area 3. Trusted digital solutions and cybersecurity in health and care **(Topics TDS)**

Otras acciones: premios (en conv. 2020); Instrumento PYME y FTI aparte

# Call – Better Health and care, economic growth and sustainable health systems

## 1.1. Personalised Medicine (I)

- SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities combining mental and non-mental disorders (4-6 M€/proyecto; 12-17 proyectos – total 70 (-5) M€)
- SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders (4-6 M€/proyecto; 8-12 proyectos – total 50 M€)
- SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine (1,5-2M€; 3 proyectos – total 8 M€ - 1 proyecto/año)

# 1.1. Personalised Medicine – New topic proposal (draft!)

## SC1-BHC-30-2019: Towards risk-based screening strategies in non-communicable diseases

- **Specific challenge:** Prevention and early detection based on more effective screening for more effective treatments, better disease control and care.
- **Scope:** Proposals should **develop new or refined targeted screening interventions aiming at identifying populations or groups at high risk of developing disease.** Stratification by health risk factors and determinants such as e.g. genetic, exposomic, socio-economic, gender, geographic, immunological, environmental, behavioural, cultural, and lifestyle habits, should be addressed. Strategies may include the use of molecular markers and digital applications. The risk-adapted interventions should demonstrate high level of accuracy, clinical value, cost-effectiveness acceptability and the potential to be taken up by healthcare systems. Health inequities should be considered.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

- **Expected Impact:**
  - Established screening strategies, which are effective, affordable, acceptable to the population, and cost effective.
  - Demonstrated potential to improve health outcomes and equity across Europe."
- **RIA - 2 stage** – 40 M€/several projects will be funded.

## 1.1. Personalised Medicine – New topic proposal (draft!) (II)

### SC1-BHC-31-2019: Pilot actions to build the foundations of a human cell atlas

- **Specific Challenge:** The international Human Cell Atlas initiative (HCA) will create reference maps of all human cells as a basis for understanding human health as well as diagnosing, monitoring and treating diseases.
- **Scope:** Each pilot action should establish and demonstrate the utility of a technological/biological platform to generate and integrate standardised molecular and other data sets, characterising single cells or their nuclear components, their interactions and/or spatial location in tissues from one human organ.
- **Budget:** 3-5 million Euros
- **Expected impact:**
  - Effective and sustainable biological and/or technological platforms.
  - Competitive and sustainable European role in HCA
  - Strong involvement of European technology SMEs
  - Laying the groundwork for next-generation personalised medicine
- **RIA - single stage** - 20 (-5)M€/several projects will be funded.

## 1.2. Innovative health and care industry

---

- SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications (6-8M€; 6-8 proyectos – total 50 M€)
- SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis (9-11 M€; 3-4 proyectos – total 40 M€)



## 1.3 Infectious diseases and improving global health (I)

---

- SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors ( 12-15 M€; 2-3 proyectos – total 30 M€)
- SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (6-10 M€; 10-16 proyectos – total 95 (-5)M€)

## 1.3 Infectious diseases and improving global health (II)

---

- SC1-BHC-18-2019: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC) (2 - 4M€; 6-12 proyectos – total 25 M€)
- SC1-BHC-19-2019: Implementation research for maternal and child health (2-4M€; 6-12 proyectos – total 25 M€)

# SC1-BHC-32-2019: Towards a next generation influenza vaccine to protect citizens worldwide – an EU-India collaboration (II)

## SC1-BHC-32-2019: Towards a next generation influenza vaccine to protect citizens worldwide – an EU-India collaboration

- **Specific Challenge:** Despite the large danger posed by both seasonal and pandemic influenza, vaccines against flu are only moderately effective. The burden of seasonal influenza, and the ever-present threat of a new influenza pandemic, is a high priority for both Europe and India.
- **Scope:** Proposal(s) should further the advancement of next generation influenza vaccine candidate(s) with improved efficacy, safety, duration of immunity, and reactivity against an increased breadth of influenza strains making use of new knowledge of, for example, immunology; genetics and genomics; influenza transmission modelling; vaccine production, formulation and delivery methods. Proposal(s) should focus on at least pre-clinical and/or early clinical research, Proposal(s) shall include participants (at least 3) from India.
- **Budget:** EUR 6 and 10 million by project
- **Expected Impact**
  - Further the development of a vaccine that could be effective from the outset of a large-scale influenza pandemic.
  - Utilization of and/or further improvement of the human challenge model of influenza as a tool for candidate vaccine(s) assessment.
  - Contribute to the reduction of the burden of influenza outbreaks worldwide, particularly in Europe and India. Contribute to the achievement of Sustainable Development Goal 3, to ensure health and well-being for all, at every stage of life
  - Specific to India, boosting initiatives like Health Mission and Biopharma Mission [Innovate in India (i3)] of the Government of India by developing affordable biopharmaceuticals including vaccines for citizens the world over.
- **RIA - single stage - 20 (-5) M€/several projects will be funded.**

## Otros topics nuevos propuestos

- SC1-HCO-15-2019: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
  - CSA - single stage
- OA-10-2018-2019: InnovFin Infectious Diseases (InnovFin ID)
  - Type of Action: Financial Instrument
- Grant to the Coalition for Epidemic Preparedness Innovations (CEPI)

## 1.4 Innovative health and care systems - Integration of care (I)

---

- SC1-BHC-22-2019: Mental health in the workplace (2-4 M€; 7-15 proyectos – total 30 M€)
- SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in health care (18 - 20 M€; 3 proyectos – total 60 M€)

## 1.5 Decoding the role of the environment for health and well-being

---

- SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health (8-12M€; 4-6 proyectos – total 50 M€)

# Call – Digital transformation in Health and Care (I)

---

- SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment (3-5 M€; 5-7 proyectos – total 35 M€)
- SC1-DTH-05-2019: Large scale implementation of digital innovation for health and care in an ageing society (2-5 M€; 2-5 proyectos – total 10 M€)

## Call – Digital transformation in Health and Care (II)

- SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products (5-8 M€; 2-4 proyectos – total 19 M€)
- SC1-DTH-10-2019-2020: Digital health and care services (5-6 M€; 3-4 proyectos – total 22 M€)
- SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care (4-6 M€; 3-5 proyectos – total 20 M€)



## Call – Digital transformation in Health and Care (III)

- SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain (1,5 M€; 1 proyecto – total 1,5 M€)

# Call – Trusted Digital Solutions and Cybersecurity in Health and Care

---

- DT-TDS-01-2019: Smart and healthy living at home (15-20 M€; 3-4 proyectos – total 60 M€)



## Tabla de fechas (I)

<u>Conv.</u>	<u>Nº de topic</u>	<u>Apertura</u>	<u>Fecha de cierre</u>
<b>Convocatoria BHC</b>			
<b>2018</b>	SC1-BHC-15		<b>Etapa 1</b> 06.02.2018 <b>Etapa 2</b> 04.09.2018
<b>2019</b>	SC1-BHC-7 / 10 / 13 /28 SC1-HCO-1 / 2	26.07.2018	16.04.2019
	SC1-BHC-1 / 2 / 14 / 19 / 22 - 25		<b>Etapa 1</b> 02/10/2018 <b>Etapa 2</b> 16.04.2019



## Tabla de fechas (II)

<u>Conv.</u>	<u>Nº de topic</u>	<u>Apertura</u>	<u>Fecha de cierre</u>
<b>Convocatoria DTH</b>			
<b>2018</b>	SC1-DTH-10	26.07.2018	14.11.2018
<b>2019</b>	SC1-DTH-1 / 5 / 9 / 11 SC1-HCC-2	16.10.2018	24.04.2019



## Tabla de fechas (III)

Conv.	Nº de topic	Apertura	Fecha de cierre
<b>Convocatoria TDS</b>			
<b>2019</b>	DT-TDS-01	26.07.2018	14.11.2018

# Avance convocatorias 2020

## Prioridad 1.1. Personalised Medicine

---

- SC1-BHC-06-2020: Digital diagnostics – developing tools for clinical decisions integrating in vitro and in vivo diagnostics
- SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine
- SC1-HCO-03-2020: Improving EU-13 participation in EU-supported health research programmes
- SC1-HCO-14-2020: ERA-NET Place holder 2

## Priority 1.2 Innovative health and care industry

---

- SC1-BHC-08-2020: New therapies for Non Communicable Diseases
- SC1-BHC-11-2020: New, animal-free regulatory test methods for human safety testing at the horizon of 2030
- SC1-BHC-12-2020: Boosting the translation of results of health research into validated, innovative applications



## Priority 1.3 Infectious diseases and improving global health

- SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) 2
- SC1-BHC-20-2020: Using pre-commercial procurements and public procurement of innovative solutions in health care systems to: - reduce the risk of hospital-acquired infections and/or - improve integrated care
- SC1-HCO-07-2020: ERA-NET Place holder 1

## Priorities 1.4 and 1.5

---

### Priority 1.4 Innovative health and care systems – Integration of care

- SC1-BHC-24-2020: Healthcare interventions for the management of the elderly multimorbid patient

### Priority 1.5 Decoding the role of the environment for health and well-being

- SC1-BHC-29-2020: Environment, climate change and health – novel mitigating measures for improving population health

# Call – Digital Transformation and Care

---

- SC1-DTH-02-2020: Personalised early risk prediction, prevention and intervention, RIA
- SC1-DTH-04-2020: International cooperation in digital solutions and robotics for independent living
- SC1-DTH-06-2020: Accelerating the uptake of *in-silico* methods for testing medicines with dermatological use

# Call – Digital Transformation in Health and Care

---

- SC1-DTH-10-2019-2020: Digital Health and care services
- SC1-HCC-06-2020: Support to eHealth Innovation ecosystems in Europe
- SC1-HCC-07-2020: Support for European eHealth Interoperability roadmap deployment
- SC1-HCC-08-2020: Scaling up innovation for active and healthy ageing
- SC1-HCC-09-2020: Supporting deployment of eHealth in developing countries for better health outcomes

# Call – Trusted digital solutions and Cybersecurity in Health and Care

---

DT-ICT-13-2020 The smart hospital of the future

DT-TDS-04-2020 Demonstrating the potential and benefits of a European Digital Health Infrastructure for Personalised Medicine

# Presupuestos Totales \*

- Convocatoria SC1 2018: 621,19 M€
- **Convocatoria SC1 2019: 686,38 M€**
- **Convocatoria SC1 2020: 697,72 M€**

\*: pueden verse modificados

- 
1. Actualización al Reto Social 1 de HORIZON 2020
  2. Actualización de IMI2
  3. Actualización opciones European Innovation Council

# La Iniciativa de Medicamentos Innovadores 2 (IMI 2)

<http://www.imi.europa.eu/>



innovative  
medicines  
initiative

Europe's partnership  
for health



# Abierta 14ª convocatoria de IMI2

---

1. Targeted immune intervention for treatment of non-response and relapse
2. Non-invasive clinical molecular imaging of immune cells
3. Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
4. Centre of excellence – remote decentralised clinical trials

## Indicative budget

From EFPIA companies and IMI2 Associated Partners: EUR 84 920 360

From the IMI2 JU: EUR 82 357 000

## Key dates and deadlines

Publication date: 15 March 2018

Stage 1 submission start date: 15 March 2018

Stage 1 submission deadline: **14 June 2018**

Stage 2 submission deadline: 11 December 2018

# Áreas a financiar en próximas convocatorias de IMI2 (en diseño)

## 15ª convocatoria

1. Integración de actividades comunes en Plataformas de Investigación Clínica.
2. Aplicación de la tecnología 'blockchain' para desarrollo farmacéutico, producción y distribución.
3. Biopsia líquida y de tejido en enfermedades con base inmunológica.
4. Tecnologías y herramientas traslacionales seguras en patología immune.
5. Desarrollo de plataformas y validación en descubrimiento de fármacos para sinaptopatías.
6. Transformación digital de las variables clínicas en ensayos clínicos.
7. *AMR Accelerator programme Pillar A*: Programa de capacitación para acelerar y validar resultados científicos.
8. *AMR Accelerator programme Pillar B*: Hacia una red para acelerar y validar resultados científicos en tuberculosis.

# 16ª convocatoria (en diseño)

## AMR Accelerator Programme – Pillar C: Investigación en AMR

**Topic 1:** Progress new assets (One pre New Molecular Entity (preNME) and One first-time-in-human (FTIH)) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

**Topic 2:** Progress novel assets (One first-time-in-human (FTIH)) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline, and cytochrome bc drugs

**Topic 3:** Discover and progress novel assets with new mechanisms of action (1 pre-new molecular entity (NME) for tuberculosis (TB) and 1-pre- new molecular entity (NME) for non-tubercular mycobacteria (NTM) and biomarkers for TB and NTM infection

**Topic 4:** Determination of gepotidacin levels in tonsils and prostatic tissue

**Topic 5:** Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections

**Topic 6:** Functional Ethionamide Boosters. A novel combination for tuberculosis therapy


**Topic 7:** Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter

- 
1. Actualización al Reto Social 1 de HORIZON 2020
  2. Actualización de IMI2
  3. Actualización opciones European Innovation Council

# Las oportunidades en el European Innovation Council (EIC)\*

## European Innovation Council: pilot 2018-2020

€ 2.7 billion to support +5,000 SMEs and innovators



<https://ec.europa.eu/research/eic/index.cfm?pg=funding>

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020

# SME Instrument

- Funding awarded via a continuously open call, 4 cut-off dates per year
  - Phase 1 > EUR 50,000 grant (feasibility)
  - Phase 2 > EUR 0.5 Mio. to 2.5 Mio. (market-ready)
  - Phase 3: business acceleration services, including coaching, for SMEs (SMEi, FET-Open, FTI grant holders)
- Fully bottom-up: no predefined topics
- Evaluation criteria stress potential for market-creating innovation
- Forms (part B) shorter and business language
- Phase 2:
  - Quality threshold raised to 13
  - Interview by jury in second step, evaluators with technology and financial/commercial background, published early 2018
- **Specific for Health:**
  - TRL 6 or higher (so, after first clinical trials – but no eligibility criterion),
  - 70 % DCs + 25% ICs' grant (no preferential treatment for any sector)
  - € 2.5 m and 2 years are max., but more can be requested, duly justified

Budget in € millions		
2018	2019	2020
480	552	601

# Fast-Track to Innovation (FTI)

Acceleration support for industry-driven consortia to deliver market-creating, breakthrough innovation

- Funding awarded via a continuously open call -- three cut-off dates per year
- Business acceleration services, including coaching, for SMEs

## Novelties

- The evaluation criteria stress potential for market-creating innovation:

### Impact

- ✓ Solutions that can create new markets or disrupt existing ones are key targets
- ✓ Boosting (rapid) scale-up and competitiveness of European businesses

### Excellence

- ✓ Bring important progress to or revolutionise an industrial sector, business practice or societal issue
- ✓ The degree of risk: be bold
- Business acceleration services (including coaching) for SMEs
- New submission form underway

### Budget in € millions

2018	2019	2020
100	100	100

# FET Open

- Laying foundations for radically new future technologies
- From knowledge to new breakthrough technology
- High-risk / high-impact interdisciplinary research with:
  - Radical vision
  - Breakthrough technological target
  - High ambitions

## Features

- The evaluation criteria emphasise (even more) potential for science-to-technology breakthrough
- Business acceleration services (including coaching) for SMEs
- Higher budget, including for connecting consortia to markets, business, innovation and IP intelligence, the EIC community in view of accelerating the impact of the funding awarded

### Budget in € millions (more than 98% of total budget is for RIAs)

2018	2019	2020
186	166	364



# EIC Horizon Prizes

Contests for challenge-driven inducement prizes to be awarded to those best addressing the following challenges:

- ✓ Innovative Batteries for eVehicles: EUR 10 M
- ✓ Fuel from the Sun: Artificial Photosynthesis: EUR 5 M
- ✓ **Early Warning for Epidemics: EUR 5 M**
- ✓ Blockchain for Social Good: EUR 5 M
- ✓ Low-Cost Space Launch: EUR 10 M
- ✓ Affordable High-Tech for Humanitarian Aid: EUR 5 M (split-out in 1 M awards)

# Resumen oportunidades en el European Innovation Council (EIC)\*

Instrument →	SME-Instrument		FTI	FET-Open	EIC Pilot
	Phase 1	Phase 2			
For whom	One or more eligible <sup>1</sup> SMEs		From 3 to 5 eligible <sup>1</sup> entities (mostly industrial <sup>2</sup> )	At least 3 eligible <sup>1</sup> entities (some sizes)	At least 3 eligible <sup>1</sup> entities (some sizes)
Maximum funding <sup>4</sup>	50,000 €	2.5 M€	3 M€	1 M€ (RIAs) / 2 M€ (CSAs)	Varies for each prize
Total budget 2018-20	164 M€	1425 M€			40 M€
Focus	Exploring the feasibility of a business idea (~ 6 months)	Breaking into a new market	Market innovation	Radically new technologies	6 different topics (major societal issues)

**Full bottom-up and introduction of interviews are the main new features of the evaluation under EIC Pilot**

- (1) Applicants must be established in a country associated to Horizon 2020
- (2) This industry involves the inclusion of at least 60% of the budget to industry participants in the consortium, or (b) the presence of at least 3 industry participants in a consortium of three or four partners, or of three industry participants
- (3) A FET-Open consortium must include at least 3 participants from 3 different EU Member States or Associated Countries. In addition, a legal entity from anywhere in the world can also be included in the consortium.
- (4) ...

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



[EIC website](#)

\*: Fuente: Comisión Europea

## Información útil

---

- <https://www.imi.europa.eu/apply-funding/future-topics>
- [EIC website](#)
- Herramienta de seguimiento SME-Instrument: <https://sme.easme-web.eu/#>

Juan E. Riese

[jriese@eu-isciii.es](mailto:jriese@eu-isciii.es)

Tel. 918222181

Información sobre convocatorias en: <http://eu-isciii.es>

